BrainChild

Seattle

BrainChild develops locoregional CAR T cell therapies for pediatric brain tumors, including treatments delivered directly into the cerebrospinal fluid to bypass the blood-brain barrier. Its mission is to improve outcomes for children with deadly brain cancers.

Facts

HQ
Seattle
Sectors
Biotech, Healthcare, Cell therapy, Immunotherapy
Founded
2023

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about BrainChild

BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG

BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.

Questions about BrainChild

What is BrainChild?

Seattle

Where is BrainChild based?

BrainChild is headquartered in Seattle.

When was BrainChild founded?

BrainChild was founded in 2023.